ARTICLE | Finance
CAR talk
Why investors in Kite, Juno won't see near-term CAR T data in solid tumors
April 27, 2015 7:00 AM UTC
While investors in Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) will soon be combing through American Society of Clinical Oncology abstracts, they shouldn't hold their breath for efficacy data for the CAR T companies' solid tumor programs.
Many investors are hungry for such data because they think it's hard to justify the valuations of CAR T companies based on results in hematological malignancies alone. ...